147 related articles for article (PubMed ID: 10623432)
1. Use of an antibody against the soluble interleukin 2 receptor alpha subunit can modulate the stability and biodistribution of interleukin-2.
Kobayashi H; Tagaya Y; Han ES; Kim IS; Le N; Paik CH; Pastan I; Nelson DL; Waldmann TA; Carrasquillo JA
Cytokine; 1999 Dec; 11(12):1065-75. PubMed ID: 10623432
[TBL] [Abstract][Full Text] [Related]
2. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
3. Methods to avoid adverse effect of circulating antigen on biodistribution of 125I-labeled antiTac dsFv: preinjection of intact antibody versus clearance of antigen with adivin-biotin system.
Kobayashi H; Sun BF; Yoo TM; Le N; Kim MK; Paik CH; Pastan I; Waldmann TA; Carrasquillo JA
J Nucl Med; 1999 Aug; 40(8):1381-91. PubMed ID: 10450692
[TBL] [Abstract][Full Text] [Related]
4. Improved biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the alpha subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-Tac IgG.
Kobayashi H; Yoo TM; Drumm D; Kim MK; Sun BF; Le N; Webber KO; Pastan I; Waldmann TA; Paik CH; Carrasquillo JA
Cancer Res; 1997 May; 57(10):1955-61. PubMed ID: 9157991
[TBL] [Abstract][Full Text] [Related]
5. The fractional excretion of soluble interleukin-2 receptor-alpha is an excellent predictor of the interleukin-2 receptor-alpha status after treatment with daclizumab.
ter Meulen CG; Jacobs CW; Wetzels JF; Klasen IS; Hilbrands LB; Hoitsma AJ
Transplantation; 2004 Jan; 77(2):281-6. PubMed ID: 14742994
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma.
Wang LS; Chow KC; Li WY; Liu CC; Wu YC; Huang MH
Clin Cancer Res; 2000 Apr; 6(4):1445-51. PubMed ID: 10778976
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of soluble interleukin-2 receptor alpha (sIL-2Ralpha) as a predictor of outcome in brucellosis.
Makis AC; Galanakis E; Hatzimichael EC; Papadopoulou ZL; Siamopoulou A; Bourantas KL
J Infect; 2005 Oct; 51(3):206-10. PubMed ID: 16230217
[TBL] [Abstract][Full Text] [Related]
8. Epitope blocking: positive and negative effects on the biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment of two antibodies against different epitopes of the circulating antigen.
Kobayashi H; Sun BF; Han ES; Kim MK; Le N; Wang QC; Nelson DL; Pastan I; Waldmann TA; Paik CH; Carrasquillo JA
Jpn J Cancer Res; 1998 Apr; 89(4):436-44. PubMed ID: 9617350
[TBL] [Abstract][Full Text] [Related]
9. Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationships.
El Houda Agueznay N; Badoual C; Hans S; Gey A; Vingert B; Peyrard S; Quintin-Colonna F; Ravel P; Bruneval P; Roncelin S; Lelongt B; Bertoglio J; Fridman WH; Brasnu D; Tartour E
Clin Exp Immunol; 2007 Oct; 150(1):114-23. PubMed ID: 17680822
[TBL] [Abstract][Full Text] [Related]
10. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
Elg SA; Hill RB; Heldman L; Ramakrishnan S
Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
[TBL] [Abstract][Full Text] [Related]
11. Anti-soluble interleukin-2R alpha combinations measure different epitopes: comparison between different anti-sIL-2R alpha antibody combinations and a newly developed in-house sIL-2R alpha sandwich ELISA.
Kazim K; Wild G; Ward A
J Clin Lab Immunol; 1998; 50(1):17-25. PubMed ID: 10189613
[TBL] [Abstract][Full Text] [Related]
12. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
Bien E; Balcerska A
Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
[TBL] [Abstract][Full Text] [Related]
13. Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders.
Zwirska-Korczala K; Berdowska A; Jochem J; Sitkiewicz A; Birkner E; Polaniak R; Jedrzejowska-Szypułka H; Korzonek-Szlacheta I
J Clin Pharm Ther; 2004 Apr; 29(2):151-6. PubMed ID: 15068404
[TBL] [Abstract][Full Text] [Related]
14. A monoclonal antibody 7G7/B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac.
Rubin LA; Kurman CC; Biddison WE; Goldman ND; Nelson DL
Hybridoma; 1985; 4(2):91-102. PubMed ID: 2408992
[TBL] [Abstract][Full Text] [Related]
15. G-CSF therapy and catheter-related Gram-positive sepsis increase serum IL-2 receptor α level and may falsely suggest a relapse in children with soft tissue sarcomas unless serum beta2-microglobulin, lactate dehydrogenase and C-reactive protein levels are determined concomitantly.
Bien E; Balcerska A; Niedzwiecki M; Krawczyk M; Rapala M; Trzonkowski P; Stepinski J
Cytokine; 2011 Sep; 55(3):347-52. PubMed ID: 21640605
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 2 (IL-2) variants engineered for increased IL-2 receptor alpha-subunit affinity exhibit increased potency arising from a cell surface ligand reservoir effect.
Rao BM; Driver I; Lauffenburger DA; Wittrup KD
Mol Pharmacol; 2004 Oct; 66(4):864-9. PubMed ID: 15385640
[TBL] [Abstract][Full Text] [Related]
18. Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma.
Yang ZZ; Grote DM; Ziesmer SC; Manske MK; Witzig TE; Novak AJ; Ansell SM
Blood; 2011 Sep; 118(10):2809-20. PubMed ID: 21719603
[TBL] [Abstract][Full Text] [Related]
19. Soluble cytokine receptors as carrier proteins: effects of soluble interleukin-4 receptors on the pharmacokinetics of murine interleukin-4.
Ma Y; Hurst HE; Fernandez-Botran R
J Pharmacol Exp Ther; 1996 Oct; 279(1):340-50. PubMed ID: 8859012
[TBL] [Abstract][Full Text] [Related]
20. Increased serum-soluble interleukin-2 receptor in burn patients: characterization and effects on the immune system.
Jobin N; Garrel D; Bernier J
Hum Immunol; 2000 Mar; 61(3):233-46. PubMed ID: 10689113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
